- Home
- FATE vs WHWK Comparison
FATE vs WHWK Comparison
Compare FATE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- WHWK
- Stock Information
- Founded
- FATE 2007
- WHWK 2007
- Country
- FATE United States
- WHWK United States
- Employees
- FATE N/A
- WHWK N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- WHWK Health Care
- Exchange
- FATE Nasdaq
- WHWK Nasdaq
- Market Cap
- FATE 116.5M
- WHWK 95.2M
- IPO Year
- FATE 2013
- WHWK N/A
- Fundamental
- Price
- FATE $1.06
- WHWK $2.20
- Analyst Decision
- FATE Buy
- WHWK
- Analyst Count
- FATE 7
- WHWK 0
- Target Price
- FATE $3.92
- WHWK N/A
- AVG Volume (30 Days)
- FATE 2.1M
- WHWK 5.2M
- Earning Date
- FATE 11-12-2025
- WHWK 11-06-2025
- Dividend Yield
- FATE N/A
- WHWK N/A
- EPS Growth
- FATE N/A
- WHWK N/A
- EPS
- FATE N/A
- WHWK N/A
- Revenue
- FATE $8,470,000.00
- WHWK $21,596,000.00
- Revenue This Year
- FATE N/A
- WHWK N/A
- Revenue Next Year
- FATE N/A
- WHWK N/A
- P/E Ratio
- FATE N/A
- WHWK N/A
- Revenue Growth
- FATE N/A
- WHWK N/A
- 52 Week Low
- FATE $0.66
- WHWK $1.39
- 52 Week High
- FATE $3.50
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- FATE 37.34
- WHWK 50.81
- Support Level
- FATE $1.00
- WHWK $2.01
- Resistance Level
- FATE $1.51
- WHWK $2.27
- Average True Range (ATR)
- FATE 0.15
- WHWK 0.17
- MACD
- FATE -0.05
- WHWK -0.03
- Stochastic Oscillator
- FATE 6.38
- WHWK 43.27
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.